Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.69 |
| ▸ | CLK1 | P49759 | 2/20 | 0.69 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.69 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.69 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.69 |
| ▸ | CLK3 | P49761 | 1/20 | 0.69 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.69 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862951 | 1.00 | PIM1 (0.69) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL6418533 | 0.85 | MEN1 (0.51) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL497536 | 0.81 | PIM1 (1.00) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL497535 | 0.81 | PIM1 (1.00) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL497027 | 0.78 | CISD1 (0.77) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL497028 | 0.78 | CISD1 (0.77) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL26094619 | 0.78 | MEN1 (0.58) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL14033097 | 0.77 | DYRK3 (0.70) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL1250384 | 0.75 | PIM1 (1.00) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG | |
| SCHEMBL1250382 | 0.75 | PIM1 (1.00) | PIM1PIK3CDCSNK2A2PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084804-A1 | Quinazoline thiazolinones | CDK1, CDK14, CDK18 | PIM1 496/4885PIK3CD 1067/4885CSNK2A2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.